30
Participants
Start Date
April 20, 2022
Primary Completion Date
October 11, 2022
Study Completion Date
October 11, 2022
Tocilizumab/Actemra® (Roche)
The infusion of tocilizumab will antagonize IL-6 signaling for the duration of the study, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
Saline 9%
The infusion of saline will serve as placebo for tocilizumab, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
Centre for Physical Activity Research, Rigshospitalet Section 7641, Copenhagen
Helga Ellingsgaard
OTHER